Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Hematopoietic and Lymphatic System Neoplasm 8Malignant Solid Neoplasm 7Solid Tumor 2Hematopoietic and Lymphoid System Neoplasm 2Advanced Malignant Solid Neoplasm 2Stomach Neoplasms 1Solid Tumors 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Rectal Neoplasms 1Pelvic Neoplasms 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Malignant Female Reproductive System Neoplasm 1Liposarcoma 1Fallopian Tube Neoplasms 1Desmoplastic Small Round Cell Tumor 1Colonic Neoplasms 1Chemotherapy-Induced Peripheral Neuropathy 1Advanced Rare Malignant Solid Neoplasm 1

Interventions

atezolizumab 1Tiragolumab 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Rare Malignant Solid Neoplasm × Specimen Handling × Other solid neoplasm × Clear all
NCT05715281 2025-11-25

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
12 enrolled
Other solid neoplasm

Advanced Rare Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡